Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Background Data are limited regarding transcatheter aortic valve replacement (TAVR)‐related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results Data were collected from 90 patients who underwent TAVR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2015-01, Vol.85 (1), p.118-129
Hauptverfasser: Flaherty, Michael P., Mohsen, Amr, Moore, Joseph B., Bartoli, Carlo R., Schneibel, Erik, Rawasia, Wasiq, Williams, Matthew L., Grubb, Kendra J., Hirsch, Glenn A.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Aged, 80 and over
Aortic Valve Stenosis - therapy
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Cardiac Catheterization - methods
Chi-Square Distribution
Clinical outcomes
Drug therapy
Female
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - adverse effects
Heart Valve Prosthesis Implantation - instrumentation
Heart Valve Prosthesis Implantation - methods
Humans
Kentucky
Logistic Models
Male
Multivariate Analysis
Odds Ratio
Platelet Count
Predictive Value of Tests
predictors
Prosthesis Design
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
TAVR
thrombocytopenia
Thrombocytopenia - blood
Thrombocytopenia - diagnosis
Thrombocytopenia - etiology
Time Factors
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Data are limited regarding transcatheter aortic valve replacement (TAVR)‐related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri‐procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No‐TP) group 1, acquired (new) TP (NTP) group 2, pre‐existing (pre‐TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100–149 × 103 cell/µL) and moderate–severe (MS) TP (
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.25668